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Background: Rheumatoid arthritis (RA) is a chronic inflammatory disorder that leads to joint damage, deformity,
and pain. It affects approximately 1% of adults in developed countries. Periodontitis is a chronic oral infection,
caused by inflammatory reactions to gram-negative anaerobic bacteria, and affecting about 35 to 50% of adults. If
left untreated, periodontitis can lead to tooth loss. A significant association has been shown to exist between
periodontitis and RA in observational studies. Some intervention studies have suggested that periodontal treatment
can reduce serum inflammatory biomarkers such as C-reactive protein, or erythrocyte sedimentation rate. We
hypothesize that periodontitis could be an aggravating factor in patients with RA, and that its treatment would
improve RA outcomes. The aim of this clinical trial is to assess the effect of periodontal treatment on the biological
and clinical parameters of patients with RA.
Methods/design: The ESPERA (Experimental Study of Periodontitis and Rheumatoid Arthritis) study is an
open-label, randomized, controlled trial. Subjects with both RA and periodontitis will be recruited at two university
hospitals in southwestern France. In total, 40 subjects will be randomized into two arms (intervention and control
groups), and will be followed up for 3 months. Intervention will consist of full-mouth supra-gingival and
sub-gingival non-surgical scaling and root planing, followed by systemic antibiotic therapy, local antiseptics, and
oral hygiene instructions. After the 3-month follow-up period, the same intervention will be applied to the subjects
randomized to the control group.
The primary outcome will be change of in Disease Activity Score in 28 Joints (DAS28) at the end of the follow-up
period. Secondary outcomes will be the percentages of subjects with 20%, 50%, and 70% improvement in disease
according to the American College of Rheumatology criteria. Health-related quality of life assessments (the Health
Assessment Questionnaire and the Geriatric Oral Health Assessment Index) will also be compared between the two
groups.
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Discussion: Evidence-based management of potential aggravating factors in subjects with active RA could be of
clinical importance, yet there are few randomized controlled trials on the effect of periodontal treatment on the
clinical parameters of RA. The ESPERA trial is designed to determine if non-surgical periodontal treatment could
improve clinical outcomes in patients with active RA, and the quality of life of these patients.
Trial registration: The ESPERA Trial was registered in Current Controlled Trials [ISRCTN79186420] on 2012/03/20.
The trial started recruiting on 2012/03/06.
Keywords: Rheumatoid arthritis, Periodontal diseases, Periodontitis, Randomized controlled trial, ProtocolBackground
Rheumatoid arthritis (RA) is a chronic and destructive
systemic autoimmune disease, characterized by the accu-
mulation and persistence of inflammatory infiltrates in
the synovial membrane, and the inflammatory condition
of joints, tendons, and periarticular structures [1,2]. If
untreated, the inflammatory condition can lead to de-
struction of the bone and cartilage of joints, and also of
ligaments and soft tissues, causing severe disability,
clinically important impact on quality of life (QOL), and
substantial effects in terms of cost and productivity loss
[3]. RA affects approximately 0.3% of patients in France
[4], with a usual female:male sex ratio of 3:1 [5].
Periodontal diseases are diseases that affect the tissues
supporting the teeth. The first step in the gum-disease
process is gingivitis, an immune-inflammatory response
to the bacterial colonization of tooth surfaces, without
bone loss. Gingivitis can progress into periodontitis, an
advanced and more serious stage of gum disease, which
includes alveolar bone loss, eventually leading to tooth
loss [6]. Periodontitis is a chronic oral infection caused
by inflammatory reactions to gram-negative anaerobic
bacteria, and affecting about 35 to 50% of adults [7,8].
Several recent research studies have shown that peri-
odontitis could have an important influence on systemic
inflammatory loading, and could trigger or worsen many
medical conditions, including myocardial infarction and
stroke [9,10], unbalanced glycemic control in patients
with diabetis [11,12], preterm births [13,14], occurrence
of chronic obstructive pulmonary disease and respiratory
complications [15], or even erectile dysfunction [16].
RA and periodontitis share some pathogenic features;
both are chronic inflammatory diseases with genetic and
environmental influences and immunoregulatory imbal-
ance, and both lead to destruction of conjunctive and hard
tissues [17,18]. A study has reported that the frequency of
RA is significantly higher in patients with periodontal dis-
ease than in subjects without periodontitis (3.95% versus
0.66%) [17]. Other studies have reported a higher inci-
dence of missing teeth, dental plaque, greater periodontal
pocket depth, or worse clinical attachment levels in
patients with RA [18-20]. On the one hand, it is likely thatpatients with RA may encounter more difficulties in
achieving good oral health because of joint pain or func-
tional limitation [20,21], while on the other hand, it is hy-
pothesized that periodontitis could be a risk factor or an
aggravating factor for RA. In particular, the role of
Porphyromonas gingivalis, a well-known periodontopatho-
genic bacterium, has been widely highlighted, because
this oral bacterium has an endogenous peptidylarginine
deiminase enzyme [22]. This enzyme is responsible for
citrullination of arginine residuals, which is one of the
crucial first steps in the development of RA [23-25].
A few studies have shown that periodontal treatment
might induce a significant decrease in erythrocyte sedi-
mentation rate (ESR) or Disease Activity Scores in 28
joints (DAS28) [26-29]. Further prospective studies, espe-
cially randomized controlled trials, are needed to deter-
mine whether full management of periodontitis in patients
with RA results in improved clinical or QOL outcomes.
The aim of this study is to assess the effect of periodontal
treatment on the parameters of RA.
Methods
The recommendation of the Consolidated Standards
of Reporting Trials (CONSORT) statement will be
followed [30].
General design
The ESPERA (Experimental Study of PEriodontitis and
Rheumatoid Arthritis) trial is an open-labeled, randomized
controlled clinical study. This trial is bicentric (Toulouse
and Bordeaux University hospitals, France), with two
parallel groups (‘immediate’ periodontal treatment ver-
sus ‘delayed’ periodontal treatment, with a balanced 1:1
treatment allocation), and with 3 months follow-up for
both groups.
Objectives
The primary objective of this trial is to analyze the
hypothesis that periodontal treatment in subjects with
RA will lead to a decrease in RA activity as, measured
by DAS28 [31], after 3 months of follow-up in subjects
suffering with both periodontitis and RA. The null
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DAS28 in subjects with RA.
The secondary objectives are to assess whether peri-
odontal treatment is associated with: 1) an improvement
in RA, judged using American College of Rheumatology
criteria (ACR) criteria (20%, 50% or 70% improvement;
ACR 20, ACR50, or ACR70) [32]; 2), an increase in
QOL as measured by the Health Assessment Question-
naire (HAQ) score [33,34]; and 3), an increase in oral




Volunteers will be recruited from two Rheumatology De-
partments of southwestern France (Toulouse University
Hospital and Bordeaux University Hospital). Patients who
are referred to the either rheumatology department and
have a positive diagnosis of RA (according to the 1987
revised American Rheumatism Association criteria for
the classification of RA [36]) will be screened for pos-
sible inclusion. Pre-inclusion and exclusion criteria will
be checked at V0, by rheumatologists in each center,
using a standardized questionnaire.
V0: screening visit
Pre-inclusion criteria
 Age 18 years or older (of either gender).
 Affiliated to a health insurance scheme.
 RA diagnosed at least 1 year before V0.
 DAS28 score between 3.2 and 5.1 during the month
preceding V0.
 No change in medication, dose, or formulation in
RA treatment during the 3 months preceding V0.
 Available for all study visits over 3 months
(V1 to V4).
 Presence of at least six natural teeth.
 Ability to give written informed consent.
Exclusion criteria
 Planned hospitalization for pre-existing condition
apart from RA within 3 months after V0.
 Risk of infection:
◦ Presence of one or more known infectious
diseases (HIV, hepatitis, infectious mononucleosis).
◦ Known clinically important renal disease
(creatinine clearance < 60 ml/min) or liver disease.
◦ Unbalanced diabetes.
◦ Known risk of endocarditis.
 Permanent pacemaker [37].
 Use of anti-thrombotic treatment (heparin, anti-
vitamin K). Severe difficulties in understanding written and
spoken French.
 Chronic disorder requiring chronic or intermittent
use of antibiotics.
 Known hypersensitivity to chlorhexidine
digluconate.
 Participation in another intervention study.
 Known contraindications to both amoxicillin and
clindamycin.
 Known contraindications to dental local anesthetic.
 Pregnancy or lactation or intent to become
pregnant.
V1 - inclusion visit
Inclusion criteria
 No change relative to pre-inclusion criteria or
exclusion criteria at V0.
 Periodontitis (at least one site with periodontal
probing depth ≥ 4 mm and clinical attachment
level ≥ 3 mm on at least four different teeth).
 Moderate RA activity according to European League
Against Rheumatism (EULAR) criteria, defined as
DAS28 of 3.2 to 5.1 [38].
 Provision of informed consent (after 1 week cooling-
off period).
 No planned changes in medication, dose or
formulation of RA treatment during the following 3
months. No change in disease modifying anti-
rheumatic drug treatment will be allowed during the
3 months of the study duration. In cases of painful
flare, (defined as an increase of more than 0.6 on the
DAS28, or as a pain assessed as greater than 50 on a
visual analog scale), use of analgesic (non-steroidal
anti-inflammatory drug or at worst, morphine
derivatives) or steroidal anti-inflammatory drug
(cure in less than 6 days) will be allowed. If these are
insufficient, then if the patient’s condition requires
it, a treatment change can be established by medical
staff. In such cases, patient will not be excluded
from the study but it will be taken into account in
the statistical analyses (see section on Statistical
methods).
Exclusion criteria
A subject will not qualify for enrolment if she/he presents
at least one of the following.
 Acute oral infection.
 Acute dental pain (including pulpitis).
 Suspicious oral mucosal lesion requiring further
analysis.
 Severe oral inflammation unrelated to periodontal
conditions.
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severe mucosal inflammation.
 Need for immediate tooth extraction.
Hospital-based oral care will be offered to such subjects,
and the re-inclusion into the trial will be re-evaluated after
remission of symptoms or required delay.Exclusion criteria (all stages)
Subjects will be excluded from the trial if they no longer
wish to participate for any reason.Study timelines
Subjects will be invited to participate after a brief
explanation provided by the rheumatologist at V0. If
they agree, they will be given an information sheet and
the informed consent document, so they can read them
before the next visit. The study dentist will contact the
subjects to make an appointment (V1) within 3 weeks in
the same rheumatology center. During V1, subjects will
receive more detailed information about periodontal
diseases and, if they are still willing to participate, they
will give their written consent. At this point, all subjects
will have an appointment with the dentists to undergo
periodontal treatment (V2) within 15 days after V1.
Subjects will then be randomly assigned to one of the
groups and will be contacted by phone within 3 days to
confirm or cancel the V2 appointment, depending on
whether they belong to the immediate or delayed treat-
ment group. Both groups will then be followed up for 3
months.
Subjects from the immediate treatment group will
receive a control visit 3 weeks after V2 (V3) and a final
visit at 3 months (V4).Figure 1 Study timelines.Subjects from the delayed treatment group will also
have the V4 appointment, at which they will receive
the periodontal treatment and will also have a control
visit (V5).
Control visits will be used to check for proper healing
of periodontal tissues and to repeat oral health hygiene
instructions. The study timelines are presented in
Figure 1 and details of study schedules are summarized
in Table 1.
Randomization
The random allocation sequence will be generated using a
computer number generator to select random permuted
blocks. The block lengths will be 2, 4, 6 and 8 and will vary
randomly. The random allocation sequence will be
performed using R software (version 2.12.1) and the add-
itional package ‘blockrand’ (version 1.2). Randomization
cards will be printed out and sealed in sequentially num-
bered, opaque envelopes by an independent research as-
sistant prior to the beginning of the trial. Randomization
will be stratified by center. Subjects meeting the eligibility
criteria at V1 will be randomly assigned to receive peri-
odontal treatment within 15 days after V1 (immediate
treatment group) or after the 3 months follow-up period
(delayed treatment group (control)).
Intervention
Periodontal treatment will be performed by trained and
assessed dental investigators. Periodontal treatment is
proposed as a comprehensive package including dental
biofilm staining, full-mouth disinfection, non-surgical
scaling and root planing, systemic antibiotic (ATB) ther-
apy, and oral health hygiene instructions. The periodontal
intervention will be performed at V2 for the immediate
treatment group and at V4 for the delayed treatment
Table 1 Study schedule
V0 V1 V2 V3 V4 V5
“Immediate” treatment group
Review of pre-inclusion criteria x
Review of selection criteria x
Written informed consent x
Initial questionnaire x
DAS28 assessment x x
ACR assessment x x
HAQ and GOHAI self-questionnaires x x
Full periodontal assessment x x
Periodontal treatment x
Oral hygiene instructions x x
Final questionnaire x
Next visit appointment x x x x
“Delayed” treatment group
Review of pre-inclusion criteria x
Review of selection criteria x
Written informed consent x
Initial questionnaire x
DAS28 assessment x x
ACR assessment x x
HAQ and GOHAI self-questionnaires x x
Full periodontal assessment x x
Periodontal treatment x
Oral hygiene instructions x x
Final questionnaire x
Next visit appointment x x x
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neither periodontal treatment nor a placebo before V4.
Finally, both groups will receive exactly the same
intervention.
Scaling and root planing
A disclosing solution (Dento-Plaque Inava; Pierre Fabre,
Gien, France) will be used to color the dental biofilm
before starting the removal of supra-gingival and sub-
gingival plaque and calculus. Scaling and root planing
(SRP) will be performed using both hand instruments
(Gracey curettes; Henry Schein, Alfortville, France) and
an ultrasonic system. An ultrasonic generator (P-Max
Satelec; Acteon, Mérignac, France) with specific micro
instruments (H3, P2L, and P2R), using reduced power
bands and a slight lateral pressure, will be used to per-
form mechanical debridement, under local anesthetic if
necessary (in case of pain or on patient’s request).
Chemical sub-gingival disinfection will be used along
with the ultrasonic debridement, using an antisepticmouth rinse (chlorhexidine 0.12%, Eludril Gé; Pierre
Fabre).
Systemic (ATB) therapy
AFSSAPS (Agence Francaise de Securite Sanitaire des
Produits de Sante (the French agency for the safety of
health products)) and HAS (Haute Autorité de Santé (the
French national health authority) recommend prophylac-
tic ATB therapy for patients at risk of immunodeficiency
undergoing periodontal treatment [39]. Sufficient amoxi-
cillin (GlaxoSmithKline, Mayenne, France) for 7 days will
be given to subjects on the day of the periodontal treat-
ment. In case of contraindication to β-lactam ATBs,
clindamycin (Pfizer, Paris, France) will be given. The de-
tailed ATB therapy prescription will be adapted to each
subject, based on 500 mg amoxicillin three times daily
(morning, midday, and evening) for 7 days, or 300 mg
clindamycin twice daily (morning and evening) for 7 days.
Oral hygiene instructions
Oral hygiene instruction (OHI) will be given by the dental
investigators just after the periodontal treatment (that is,
during V2 or V4, depending on randomization), and
during V3 for the immediate treatment group or V5 for
the delayed treatment group. A 15-minute oral session
will include visual and verbal information on how to use a
toothbrush, inter-space brushes, dental floss, and mouth-
wash correctly; how to clean bridges and dentures; and
how and why to use a plaque disclosing test to perform
tooth cleaning.
A full kit containing all the hygiene products necessary
for 3 months of oral hygiene will be given to the patient at
the end of the intervention. It will include three 75 ml
tubes of chlorhexidine digluconate toothpaste (0.12%), 20
meters of dental floss, three soft toothbrushes, 12 single-
tufted inter-space brushes, and a quantity of plaque dis-
closing tablets (Red-Cote; Gum Sunstar, Levallois Perret,
France). A 300-ml bottle containing an antiseptic mouth-
wash product (chlorhexidine digluconate 0.12%, Sunstar
Paroex; Chemineau Laboratories, Vouvray, France) will be
given, with recommendations to use 10 ml of the product
three times a day after tooth brushing for a period of 10
days after the periodontal treatment session. Leaflets
with pictorial information, summarizing the various oral
hygiene steps, will be included in the kit.
Outcomes
The primary outcome is change in the DAS28 between V1
and V4. Secondary outcomes are difference in matching
ACR20, ACR50, and ACR70 criteria, and changes in HAQ
and GOHAI scores, between V1 and V4.
The assigned rheumatologist, who will be blinded to the
patient’s assigned periodontal treatment group, will assess
DAS28 [38], which is a continuous composite score (0 to
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joints (out of the 28 evaluated joints); the ESR, which
measures the degree of inflammation in the blood; and the
patient’s global assessment of health. They will also assess
the improvement in RA using the ACR criteria [32], and
will review medical forms for each participant’s safety. The
same rheumatologist will perform outcomes measures be-
tween V1 and V4. The health status of the enrolled sub-
jects will also be assessed by the same rheumatologist
throughout the monthly routine visits during the 3
months follow-up period. Interim or post-V4 data will be
used in case of absence at V4.
Assessed dental investigators will be responsible for
performing a standardized periodontal probing assessment
at V1 and V4. The full-mouth periodontal probing will be
performed using a constant pressure probe (Florida
Probe®; Gainesville, Fl, USA), from six sites per tooth
(mesiobuccal, mid-buccal, distobuccal, mesiolingual, mid-
lingual and distolingual). Periodontal assessment will in-
clude measurement of periodontal pocket depth (PPD) in
millimeters, clinical attachment level (CAL; in millimeters)
and bleeding on probing (yes/no). No radiographs will be
taken. Periodontitis will be defined by the presence of at
least one site with PPD ≥ 4 mm and CAL ≥ 3 mm on at
least 4 different teeth.
Finally, participants will self-complete questionnaires
assessing QOL (HAQ and GOHAI). They will also be
asked to complete initial and final questionnaires at V1
and V4, which will assess medical, social, and oral health
behavior information, and assess changes during the 3-
month follow-up period. Adverse events (AEs) during
the follow-up period will be reported, and these will
include unexpected study-related events and serious AEs
regardless of cause.
Statistical methods
Sample size calculation is based on detecting a difference
of 0.6 points in DAS28 change from baseline between the
two groups; 0.6 was chosen because it is the minimum
therapeutic response according to EULAR [38]. Assuming
a standard deviation of 0.6 [28] and using a two-sided test
at the 5% significance level, enrolling 16 participants per
group would yield 80% power (epiR package 0.9-30). An-
ticipating a 25% dropout rate, the target sample size was
thus set at 40 participants.
After data cleaning, preliminary analyses will investigate
the pattern of missing baseline and follow-up data. Base-
line characteristics per group will be presented as mean,
median, and standard deviations for quantitative variables,
and as absolute and relative frequency for qualitative
variables. Descriptive statistics will be provided for
the intention-to-treat population to explore whether the
randomization results in a balanced distribution of partici-
pants’ characteristics between the two groups.All baseline analyses will be performed in accordance
with intention-to-treat principles, regardless of the sub-
ject's presence at intermediate visits, the degree of com-
pliance with the periodontal treatment, or any change in
RA medication.
The main analysis will be a comparison between the
two study groups concerning the change in the DAS28
scores from baseline to 3 months in a multivariate
model, adjusted for clinical center, and considering the
rest of the independent measures (including any change
in RA medication) as possible modifying factors. The
data will be secondarily analyzed using the ‘per protocol’
approach, in which the analysis will be restricted to par-
ticipants who have complied with the treatment protocol
(SRP, ATB, and OHI) and have had no changes in RA
medication during study participation.
In addition to the primary analysis, five binary outcomes
for DAS28 at 3 months (a relative decrease greater than
10%, a 3-month level of less than 3.2, an absolute decrease
greater than 0.6, a relative increase greater than 10% and
an absolute increase greater than 0.6) will be evaluated
in logistic regression models. For secondary outcomes,
continuous variables will be analyzed through analysis
of covariance, using a model similar to that specified for
the primary outcome.
Missing outcome data will be handled as described by
Ware et al. [40] and Little et al. [41]. For participants
who discontinue any of the periodontal treatments (SRP,
ATB, or OHI) because of AEs or simple inconvenience,
efforts will be made to obtain their consent for the collec-
tion of data on outcomes. Second, we will limit the burden
and inconvenience of data collection on the participants,
and make the study experience as positive as possible. For
example, the DAS28 assessment will be performed in the
clinical center where participants are usually followed for
their RA treatment. Third, investigators will be trained
that keeping participants in the trial until the end is im-
portant, regardless of whether they continue to receive the
assigned treatment. This information will also be conveyed
to study participants. Finally, missing outcome data will be
handled using estimating-equation methods [42,43]. Com-
plete cases will be weighted by the inverse of an estimate
of the probability being observed. Efficacy of periodontal
treatment will be assessed, as will the correlation between
clinical response to periodontal treatment and DAS28
scores. The proportion of subjects who have one or more
AEs in the two groups will be compared by Fisher's exact
test. Analyses will be performed by R software (http://
www.R-project.org).
Ethics
The protocol and procedures have been approved by
ethics and regulatory agencies, and will be implemented in
accordance with the provisions of the Declaration of
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Protection des Personnes CPP (Committee for the Protec-
tion of Research Subjects), Sud-Ouest Outre-Mer I), ap-
proved the protocol on July 11, 2011 (number 1-10-37]).
AFSSAPS approved it on November 4, 2010 (number
2010-A01193-36). The trial is registered on Current
Controlled Trials under the number ISRCTN79186420
(http://www.controlled-trials.com/ISRCTN79186420/espera).
The informed consent form will contain the following
information: names and affiliations of investigators, a plain
language description of the study (treatment group, con-
trol group, and intervention), the duration of the study,
the right to withdraw at any time, the ethics committee
approval, and the privacy guarantee. All patients will re-
ceive free periodontal treatment (immediate or delayed),
and will be fully informed of the potential AEs of peri-
odontal treatment. The foreseeable risks are those conven-
tionally attributed to periodontal treatment: temporary
tooth sensitivity, temporary dental pain, side effects linked
to oral antiseptics use, and side effects linked to oral ATB
therapy.Discussion
Evidence-based management of potential aggravating
factors in subjects with active RA could be of clinical
importance. We hypothesize that periodontitis could be
an aggravating factor for RA. However, there are few
randomized controlled trials about the effects of peri-
odontal treatment on the clinical parameters of RA.
The ESPERA trial is designed to determine if non-
surgical periodontal treatment could improve clinical
outcomes in patients with active RA, and also improve
their QOL.
Our trial has a small sample size, and a potential lack
of power. However, the ESPERA trial has a conventional
80% power to detect a difference of 0.6 points in DAS28
change from baseline between the two groups, and 0.6
is the minimum therapeutic response according to
EULAR [38]. We acknowledge that 0.6 mean improve-
ment could be considered as relatively large, but two
other trials have shown such an improvement [27,28].
Furthermore, the sample size corresponds to our source
population of outpatients with both RA and periodon-
titis, as reported in a recently published observational
study [45]. Because small trial size should not be used
to justify low-quality trials, efforts will be made to
minimize sources of bias, and to enhance the reliability
of the results of the ESPERA trial. Selection bias will be
prevented through randomization, and special attention
will be paid to securing strict implementation of the
random sequence. Performance bias will be unavoidable,
because there is no possible placebo for periodontal treat-
ment; however, detection bias will be prevented throughthe blinding of RA outcome assessors. Finally, attrition
bias will be assessed at the end of the trial.
A strong feature of the current trial is that the expected
benefit for the patient could be a contribution to the
stabilization of the disease, or a slight clinical improve-
ment in RA. This could reduce the need for escalating
therapy related to insufficient control of the disease, and
improve QOL in patients with RA. In long term, peri-
odontal treatment could be integrated in the rheumatolo-
gist’s associated therapeutic arsenal.
Results of this trial could have an influence on clinical
practice, and potentially contribute to further develop-
ment of new research directions for both odontologists
and rheumatologists.
Trial status
The first patient was enrolled on March 6, 2012. The
study is ongoing, and thus far has enrolled nine patients.
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